[go: up one dir, main page]

ES2566482T3 - Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos - Google Patents

Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos Download PDF

Info

Publication number
ES2566482T3
ES2566482T3 ES10746439.8T ES10746439T ES2566482T3 ES 2566482 T3 ES2566482 T3 ES 2566482T3 ES 10746439 T ES10746439 T ES 10746439T ES 2566482 T3 ES2566482 T3 ES 2566482T3
Authority
ES
Spain
Prior art keywords
group
substituted
linear
alkyl
branched alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10746439.8T
Other languages
English (en)
Inventor
Cheol-Hyoung Park
Hye-Kyung Min
Mi-Jung Lim
Ji-Won Lee
Jin-Yong Chung
Choon-Ho Ryu
Yeo-Jin Yoon
Mi-Kyung Ji
Joo-Young Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2566482T3 publication Critical patent/ES2566482T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un derivado de azol sustituido representado por la siguiente Fórmula (I) o sales farmacéuticamente aceptables del mismo: **Fórmula** en donde, R se selecciona del grupo que consiste de C7-C15 arilalquilo no sustituido o sustituido por al menos uno seleccionado del grupo que consiste de halógeno, trifluorometilo, trifluoroalcoxi, -NO2, C(>=O)OCH3, C1-C6 alquilo lineal o ramificado, C1-C6 alcoxi, fenilo, feniloxi, benciloxi, -C(>=O)H, -OH y -CH>=N-OH; C4-C15 heteroarilalquilo no sustituido o sustituido por al menos uno seleccionado del grupo que consiste de halógeno, C(>=O)OCH3, C1-C6 alquilo lineal o ramificado, C1-C6 alcoxi, fenilo, feniloxi y benciloxi; C1-C10 alquilo lineal, ramificado o cíclico sustituido por al menos uno seleccionado del grupo que consiste de C1-C3alquiloxi, C1-C3alquiltio, carbamato, (-OC(>=O)NH2), tert-butil- OC(>=O)NH-, -NH3+, -NH2, -OH, -C(>=O)OCH2CH3, NHC(>=O)NH2, trifluorometilsufanilo, trifluorometilo, y -CN, Y se selecciona del grupo que consiste de O y -N-R1; R1 se selecciona del grupo que consiste de H y C1-C3 alquilo lineal o ramificado; R2 se selecciona del grupo que consiste de H y halógeno; A se selecciona del grupo que consiste de O y S; B se selecciona del grupo que consiste de C y N; Z se selecciona del grupo que consiste de imidazol, pirrolidina, y tetrazol sustituido o no sustituido por al menos un sustituyente seleccionado del grupo que consiste de OH, carbamato, C1-C4 alquilo lineal o ramificado, halógeno, - NO2, -NH2,-CF3, -CN y fenilo; -OC(>=O)NR3R4; NR5R6; NHC(>=NH)NH2, y -NHC(>=O)NH2; cada uno de R3 y R4 se selecciona independientemente del grupo que consiste de H; C1-C5 alquilo no sustituido o sustituido por al menos uno seleccionado del grupo que consiste de NH2, y NR7R8; piperidina, piperazina, y diazepam no sustituido o sustituido por C1-C3 alquilo; oR3 y R4 juntos pueden formar piperidina, piperazina, imidazol, pirrolidina, triazol, tetrazol, diazepam o morfolina no sustituido o sustituido por C1-C3 alquilo; cada uno de R5 y R6 es independientemente seleccionado del grupo que consiste de C2-C3 alqueno; C2-C3 alquino; y C1-C4 alquilo lineal o ramificado sustituido por al menos uno seleccionado del grupo que consiste de -OH, -C(O)NH2, C1-C3 alcoxi, y carbamato; cada uno de R7 y R8 es al menos uno seleccionado del grupo que consiste de H y C1-C3 alquilo lineal o ramificado, cada uno de m y n es independientemente 0 o 1.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES10746439.8T 2009-02-25 2010-02-25 Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos Active ES2566482T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20090015856 2009-02-25
KR20090015856 2009-02-25
KR1020100016686A KR101220182B1 (ko) 2009-02-25 2010-02-24 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
KR20100016686 2010-02-24
PCT/KR2010/001186 WO2010098600A2 (en) 2009-02-25 2010-02-25 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same

Publications (1)

Publication Number Publication Date
ES2566482T3 true ES2566482T3 (es) 2016-04-13

Family

ID=43004459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10746439.8T Active ES2566482T3 (es) 2009-02-25 2010-02-25 Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos

Country Status (13)

Country Link
US (1) US8828992B2 (es)
EP (1) EP2401263B1 (es)
JP (1) JP5717031B2 (es)
KR (1) KR101220182B1 (es)
CN (1) CN102333764B (es)
AU (1) AU2010218584B2 (es)
BR (1) BRPI1008727B8 (es)
CA (1) CA2751343C (es)
ES (1) ES2566482T3 (es)
MX (1) MX2011008910A (es)
PL (1) PL2401263T3 (es)
RU (1) RU2578596C2 (es)
WO (1) WO2010098600A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2817304A4 (en) * 2011-07-14 2015-01-21 Biochromix Newco Ab Novel compounds and their use in therapy
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
KR102191562B1 (ko) 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
BR112015022202A2 (pt) 2013-03-14 2017-07-18 Dart Neuroscience Cayman Ltd compostos substituídos de naftiridina e quinolina como inibidores da mao
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
WO2016097004A1 (en) * 2014-12-17 2016-06-23 King's College London BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
KR101896398B1 (ko) * 2017-11-14 2018-09-07 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
CN108676001A (zh) * 2018-06-12 2018-10-19 江西师范大学 一种3-取代-5-异噁唑基-4-取代-1-1,2,3-三氮唑基甲烷化合物
US11517548B2 (en) * 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
KR20200109537A (ko) 2019-03-13 2020-09-23 충북대학교 산학협력단 1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(4-((5-(트리플루오로메틸)피리딘-2-일)옥시)사이클로헥실)유레아를 유효성분으로 하는 파킨슨 질환 예방 또는 치료용 약학적 조성물
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE248589C (es)
NL120029C (es) * 1959-09-29
GB965925A (en) * 1961-03-04 1964-08-06 Francesco Angelini Improvements in or relating to 1,2,4-oxadiazole derivatives
GB969813A (en) * 1962-03-26 1964-09-16 Francesco Angelini Improvements in or relating to 1,2,4-oxadiazole derivatives
US3245989A (en) * 1962-12-15 1966-04-12 Acraf 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
NL302496A (es) 1962-12-22
FR1386543A (fr) * 1962-12-22 1965-01-22 Shionigi & Co Préparation de composés d'isoxazole et nouveaux produits ainsi obtenus
DD248589A1 (de) * 1986-04-24 1987-08-12 Univ Berlin Humboldt Verfahren zur herstellung von substituierten 1,2,4-triazolen
DD263987A1 (de) * 1987-08-07 1989-01-18 Univ Berlin Humboldt Verfahren zur herstellung von 5-(omega-aminoalkyl)-1,2,4-oxadiazolsalzen
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
HUP9602763A3 (en) * 1996-10-09 1999-05-28 Egyt Gyogyszervegyeszeti Gyar 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
CN1151150C (zh) * 2001-02-13 2004-05-26 王建武 一类非肽血管紧张素Ⅱ受体拮抗剂Jwsartan化合物及其合成方法与用途
US20050171358A1 (en) 2002-03-07 2005-08-04 Noriko Shimozono Substituted isoxazole alkylamine derivative and agri-and horticultural fungicide
HRP20040952A2 (en) * 2002-04-26 2005-06-30 F. Hoffmann - La Roche Ag Isoquinoline derivatives
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US7903538B2 (en) 2003-08-06 2011-03-08 Intel Corporation Technique to select transmission parameters
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
ATE544765T1 (de) * 2003-12-22 2012-02-15 Leuven K U Res & Dev Imidazoä4,5-cüpyridinverbindungen und verfahren zur antiviralen behandlung
US7790730B2 (en) 2004-07-27 2010-09-07 Gilead Sciences, Inc. Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
AU2005268894B2 (en) * 2004-08-02 2010-12-16 F. Hoffmann-La Roche Ag Benzyloxy derivatives as MAOB inhibitors
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN100488979C (zh) * 2005-10-14 2009-05-20 天津药物研究院 甘草次酸-30-酰胺类衍生物及其用途
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
JP2010513283A (ja) * 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
KR20100056462A (ko) * 2007-07-13 2010-05-27 글락소스미스클라인 엘엘씨 항바이러스 화합물, 조성물 및 용도
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use

Also Published As

Publication number Publication date
EP2401263B1 (en) 2016-02-17
US8828992B2 (en) 2014-09-09
US20110301150A1 (en) 2011-12-08
KR20100097059A (ko) 2010-09-02
CA2751343C (en) 2017-04-25
MX2011008910A (es) 2011-09-08
EP2401263A4 (en) 2012-11-28
JP2012518683A (ja) 2012-08-16
JP5717031B2 (ja) 2015-05-13
BRPI1008727A2 (pt) 2016-03-08
AU2010218584A1 (en) 2011-08-18
CN102333764A (zh) 2012-01-25
KR101220182B1 (ko) 2013-01-11
EP2401263A2 (en) 2012-01-04
WO2010098600A3 (en) 2011-01-06
BRPI1008727B1 (pt) 2020-07-28
RU2011134423A (ru) 2013-04-10
HK1165798A1 (zh) 2012-10-12
AU2010218584B2 (en) 2015-12-03
RU2578596C2 (ru) 2016-03-27
PL2401263T3 (pl) 2016-08-31
CN102333764B (zh) 2016-01-06
CA2751343A1 (en) 2010-09-02
BRPI1008727B8 (pt) 2021-05-25
WO2010098600A2 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
ES2566482T3 (es) Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos
ES2528797T3 (es) Compuestos de aza-benzotiofenilo y métodos de uso
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
ES2528451T3 (es) Inhibidores de esfingosina cinasa
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
NZ616298A (en) Aryl-or heteroaryl-substituted benzene compounds
ES2222336T3 (es) Inhibidores de girasas y sus usos.
ES2548998T3 (es) Composiciones antifúngicas de azol
RU2016125306A (ru) Новые пестицидные соединения и применения
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
RU2009137363A (ru) Соединения фениламинопиримидина и их применения
JP2015520769A5 (es)
AR081626A1 (es) Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR072688A1 (es) Nucleosidos y nucleotidos biciclicos como agentes terapeuticos
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
AR069869A1 (es) Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
RU2013151803A (ru) Бициклические гетероциклические соединения и их применения в терапии
EA201170096A1 (ru) Замещенные производные пиримидона
RU2008138163A (ru) 4-фенилтиазол-5-карбоновые кислоты и амиды 4-фенилтиазол-5-карбоновой кислоты как ингибиторы polo-подобной киназы plk1
EA202191040A1 (ru) Производные флаваглина для ингибирования активации онкогена kras
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.